(Q36847555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Combination antifungal therapy: what can and should we expect? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

J R Perfect

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

11 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

297-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Immunotherapy for fungal infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution inflammatory syndrome or recurrent cryptococcal disease?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Early immune reaction after reduced-intensity cord-blood transplantation for adult patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Immune reconstitution in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Voriconazole therapeutic drug monitoring.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Decision making in antifungal monotherapy versus combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination antifungal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination antifungal therapy for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Considerations in clinical trials of combination antifungal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Galactomannan detection in computerized tomography‐based broncho‐alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Comparison of Serum Galactomannan Antigen Detection and Competitive Polymerase Chain Reaction for Diagnosing Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Panfungal PCR assay for detection of fungal infection in human blood specimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705687

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705687

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563740%20AND%20SRC:MED&resulttype=core&format=json

release_psga2gk65bgati7553sddptpp4

31 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/psga2gk65bgati7553sddptpp4

24 November 2022

mapped directly with Wikidata item

1 reference